NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Amylyx Pharmaceuticals, Inc. AMLX
5 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 5-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -144.7
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2024 · Operating -360.2% · Net -345.4%
ROE
FY2025 · ROE -61.6%
Each USD of equity lost 62 cents this year.
The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.1 | 0.4 | 0.0 | 0.0 |
| Operating income $B | −0.2 | −0.3 | 0.0 | −0.2 | −0.1 |
| EBITDA $B | −0.2 | −0.3 | 0.0 | −0.2 | −0.1 |
| Income tax $B | 0.0 | −0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.1 | −0.3 | 0.0 | −0.2 | −0.1 |
| Free cash flow $B | −0.1 | −0.2 | 0.0 | −0.2 | −0.1 |
| EPS, diluted $ | −1.53 | −4.43 | 0.70 | −3.39 | −13.35 |
| Dividend / sh $ | · | · | · | · | · |
| Payout % | · | · | · | · | · |
| ROE % | −61.6 | −100.9 | 12.7 | −209.4 | · |
| Shares out B | 0.11 | 0.07 | 0.07 | 0.07 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 20 reconciliationsAUDITED
Reconciled in 5 of 19 fiscal years. 71 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2021